Product Description
Tryptophan is an amino acid needed for normal growth in infants and for the production and maintenance of the body's proteins, muscles, enzymes, and neurotransmitters. It is an essential amino acid. This means your body cannot produce it, so you must get it from your diet.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | New Zealand | Norway | Pakistan | Poland | Russia | Serbia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: DEERFIELD IL 60015
Company CEO: José E. Almeida
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Russia, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Adenocarcinoma|Adjustment Disorders|Bone Cancer|Kidney Transplant|Liver Transplant|Neurasthenia|Prostate Cancer
Phase 2: Heart Transplant|Muscle Weakness|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREDICT-RT* | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma|Bone Cancer |
2033-12-31 |
|
| GUIDANCE | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2032-04-30 |
|
| CL-N-CP-Paed | P2 |
Not yet recruiting |
Other |
2026-09-30 |
|
| CL-N-HTX-Paed | P2 |
Not yet recruiting |
Heart Transplant |
2025-06-30 |